Pfizer stock reports higher 2026 guidance at EUR 25.28
Published on 09/30/2026 at 11:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pfizer stock (ISIN US7170811035) was trading at EUR 25.28 at Lang & Schwarz on September 30, 2026 at 11:07 a.m. CEST, down 0.08 percent versus the prior close of EUR 25.30. The company enters the next reporting cycle with higher 2026 revenue guidance and a mixed product outlook.
Q2 EPS beat by USD 0.09
In its September 3, 2026 review, Zacks reported adjusted diluted EPS of USD 0.77 for Q2 2026, versus USD 0.68 consensus. Pfizer's USD 15.03 billion revenue also exceeded the USD 14.45 billion consensus estimate, creating a USD 0.58 billion sales gap.
The quality of the growth matters. Revenue increased 1 percent operationally year over year, while sales excluding Comirnaty and Paxlovid grew 5 percent operationally in Q2 2026, according to Zacks.
Guidance midpoint rises USD 500 million
Pfizer's 2026 revenue guidance now stands at USD 60.5 billion to USD 62.5 billion, compared with USD 59.5 billion to USD 62.5 billion previously. The midpoint therefore increased from USD 61.0 billion to USD 61.5 billion, while adjusted EPS guidance stayed at USD 2.80 to USD 3.00, as Zacks detailed on September 3, 2026.
The counterweight is COVID exposure. Pfizer expects USD 4.0 billion of 2026 COVID product revenue versus USD 5.0 billion previously, while newly launched and acquired products generated USD 3.2 billion in Q2 revenue and grew 18 percent operationally, according to Zacks.
HSBC target reaches USD 30.00
HSBC raised its Pfizer price target from USD 28.00 to USD 30.00 while maintaining a Hold rating on September 10, 2026, according to MarketBeat. The revised target is USD 2.00 above the previous target, while the broader consensus target in the same September 24, 2026 overview was USD 28.39.
Pfizer's next earnings report is scheduled for November 3, 2026. The company's website listed a November 3 conference call invitation on September 22, 2026, and Investing.com also identified November 3, 2026 as the next earnings date.
Pfizer stock holds near its yearly high
At Lang & Schwarz, Pfizer stock was trading at EUR 25.28 on September 30, 2026 at 11:07 a.m. CEST, down 0.08 percent versus the prior close of EUR 25.30. Pfizer's primary NYSE quotation had a 52-week range of USD 23.62 to USD 29.21 as of September 29, 2026, while market capitalization stood at USD 163.7 billion.
Pfizer stock facts
- Company: Pfizer Inc.
- ISIN: US7170811035
- Ticker: PFE
- Primary exchange: NYSE
- Price Lang & Schwarz (as of September 30, 2026, 11:07 a.m. CEST): EUR 25.28
- Change versus prior close: minus 0.08 percent
- Prior close Lang & Schwarz (September 29, 2026): EUR 25.30
- Market capitalization: USD 163.7 billion (as of September 29, 2026)
- 52-week range: USD 23.62-29.21 (as of September 29, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: November 3, 2026
